{
    "Trade/Device Name(s)": [
        "K-ASSAY CRP (Ver.2)"
    ],
    "Submitter Information": "Kamiya Biomedical Company, LLC",
    "510(k) Number": "K242170",
    "Predicate Device Reference 510(k) Number(s)": [
        "K023828"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DCK"
    ],
    "Summary Letter Date": "March 21, 2025",
    "Summary Letter Received Date": "March 21, 2025",
    "Submission Date": "April 18, 2025",
    "Regulation Number(s)": [
        "21 CFR 866.5270"
    ],
    "Regulation Name(s)": [
        "C-Reactive Protein Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "chemistry"
    ],
    "Analyte(s)": [
        "C-reactive protein"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Potassium-EDTA tube",
        "Lithium-heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Abbott Architect c8000 analyzer",
        "Chemistry analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric assay",
        "Latex-enhanced immunoturbidimetric assay"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for K-ASSAY CRP (Ver.2), an immunoturbidimetric assay to quantify C-reactive protein in serum and plasma on clinical chemistry analyzers",
    "Indications for Use Summary": "For quantitative determination of C-reactive protein in human serum and plasma (potassium-EDTA or lithium-heparin) to aid in detection and evaluation of infection, tissue injury, inflammatory disorders, and associated diseases, for in vitro diagnostic use.",
    "fda_folder": "Immunology"
}